Literature DB >> 9445201

Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor.

A C Paulino1, B Thakkar, W G Henderson.   

Abstract

BACKGROUND: Information regarding survival and prognostic factors in children with metachronous bilateral Wilms' tumor is limited.
METHODS: A literature search of English language articles from 1950-1996 was performed. A total of 108 of 123 children with metachronous bilateral Wilms' tumor from 30 studies were evaluable for analysis. The children were classified according to the time interval to the development of a contralateral Wilms' tumor (< 18 months vs. > or = 18 months).
RESULTS: Kaplan-Meier analysis rates of overall survival for metachronous bilateral Wilms' tumor were 49.1% and 47.2% at 5 and 10 years, respectively. The median time interval to the development of a second tumor was 23.1 months. Of 106 children, 102 (96.2%) had a metachronous presentation of Wilms' tumor by 5 years. In children ages < 2 years and children ages 2-5 years, 95.2% and 93.9%, respectively, of contralateral tumors appeared within 60 months. For children ages > or = 5 years, all contralateral kidney tumors appeared by 54 months. Analysis of overall survival of patients with a time interval of < 18 months and > or = 18 months showed a 10-year survival of 39.6% and 55.2%, respectively (P = 0.024, log rank test).
CONCLUSIONS: Children with a metachronous bilateral Wilms' tumor who developed a contralateral tumor > or = 18 months from the initial diagnosis of Wilms' tumor had a better overall survival than children with a time interval of < 18 months. Children ages < 2 years at the initial diagnosis of Wilms' tumor did not have a longer period of risk for developing a contralateral kidney tumor than those ages > or = 2 years. Screening by abdominal ultrasound of the contralateral kidney for > 5 years after initial diagnosis of Wilms' tumor may not be necessary because > 95% of children had a time interval to the development of a second tumor of < or = 60 months.

Entities:  

Mesh:

Year:  1998        PMID: 9445201

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  The management of bilateral Wilms tumor.

Authors:  Derya Özyörük; Suna Emir
Journal:  Transl Pediatr       Date:  2014-01

2.  Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.

Authors:  Leo G Flores; Hsin-Hsien Yeh; Suren Soghomonyan; Daniel Young; James Bankson; Qianghua Hu; Mian Alauddin; Vicki Huff; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

Review 3.  Many faces of Wilms Tumor: Recent advances and future directions.

Authors:  Namita Bhutani; Pradeep Kajal; Urvashi Sharma
Journal:  Ann Med Surg (Lond)       Date:  2021-03-07

4.  Wilms' tumor: An update.

Authors:  Hemant B Tongaonkar; Sajid S Qureshi; Purna A Kurkure; Mary-Ann A Muckaden; Brijesh Arora; Thyavihalli B Yuvaraja
Journal:  Indian J Urol       Date:  2007-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.